{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:06:51Z","timestamp":1762459611994,"version":"3.37.3"},"reference-count":21,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To report a case of oral candidiasis that developed in a 70-year-old white female both upon initiation and rechallenge of extended-release bupropion therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Summary:<\/jats:title>\n                  <jats:p>A 70-year-old female with a past medical history of osteoarthritis, degenerative joint disease, and polycythemia vera developed oral candidiasis on 2 occasions following initiation of extended-release bupropion for the treatment of recurrent depression. During both instances, the reaction occurred with an increased dose of the medication, suggesting the adverse event may have been dose-related. The patient had no risk factors for oral candidiasis aside from dry mouth at baseline that reportedly worsened on bupropion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion:<\/jats:title>\n                  <jats:p>Though there are no other reports to our knowledge describing the development of oral candidiasis with bupropion, the likelihood of this having been an adverse reaction in this patient is probable as indicated by a calculated score of 8 from the Naranjo Algorithm. The adverse event appeared following bupropion administration and improved over time following its discontinuation. The adverse event reappeared following readministration of the agent, and no alternative causes were able to be identified. Additionally, the reaction occurred following an increase in the dose on both occasions, with the lower dose having only resulted in worsening dry mouth.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>This case demonstrates that an additional adverse event to screen for with bupropion treatment is the development of oral candidiasis. This adverse event may be more likely to occur in the older adult population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2018.07.188","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T18:49:32Z","timestamp":1530902972000},"page":"188-190","source":"Crossref","is-referenced-by-count":2,"title":["Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient"],"prefix":"10.9740","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-0317","authenticated-orcid":false,"given":"Nina","family":"Vadiei","sequence":"first","affiliation":[{"name":"(Corresponding author) Assistant Professor, The University of Arizona, College of Pharmacy Practice and Science, Tucson, Arizona, vadiei@pharmacy.arizona.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-4919","authenticated-orcid":false,"given":"Tawny L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Associate Professor, Dell Medical School at The University of Texas at Austin, Department of Psychiatry, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-1910","authenticated-orcid":false,"given":"Erica C.","family":"Garcia-Pittman","sequence":"additional","affiliation":[{"name":"Assistant Professor, Dell Medical School at The University of Texas at Austin, Department of Psychiatry, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"Suppl 1","key":"2020060307273242200_i2168-9709-8-4-188-b01","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.4103\/0973-029X.141325","article-title":"Oral candidiasis: An overview","volume":"18","author":"Singh","year":"2014","journal-title":"J Oral Maxillofac Pathol"},{"issue":"4","key":"2020060307273242200_i2168-9709-8-4-188-b02","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4088\/PCC.v06n0403","article-title":"A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor","volume":"6","author":"Stahl","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"2020060307273242200_i2168-9709-8-4-188-b03","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0149-2918(00)88301-0","article-title":"Andrew Johnston J, Ascher JA. Safety profile of sustained-release bupropion in depression: Results of three clinical trials","volume":"21","author":"Settle","year":"1999","journal-title":"Clin Ther"},{"year":"2009","key":"2020060307273242200_i2168-9709-8-4-188-b04","article-title":"Wellbutrin [package insert]"},{"issue":"3","key":"2020060307273242200_i2168-9709-8-4-188-b05","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4088\/PCC.v07n0305","article-title":"15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL","volume":"7","author":"Fava","year":"2005","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"9","key":"2020060307273242200_i2168-9709-8-4-188-b06","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/oby.2001.71","article-title":"Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women","volume":"9","author":"Gadde","year":"2001","journal-title":"Obes Res"},{"issue":"6","key":"2020060307273242200_i2168-9709-8-4-188-b07","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4088\/PCC.v01n0601","article-title":"Effect of bupropion SR on the quality of life of elderly depressed patients with comorbid medical disorders","volume":"1","author":"Fortner","year":"1999","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"2020060307273242200_i2168-9709-8-4-188-b08","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4088\/JCP.v61n0309","article-title":"Bupropion sustained release versus paroxetine for the treatment of depression in the elderly","volume":"61","author":"Weihs","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2020060307273242200_i2168-9709-8-4-188-b09","doi-asserted-by":"publisher","first-page":"411.e1","DOI":"10.1016\/j.genhosppsych.2011.01.010","article-title":"Aphthous ulcers associated with bupropion in a female adolescent: a case verified by rechallenge","volume":"33","author":"Chiang","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"2020060307273242200_i2168-9709-8-4-188-b10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/archderm.141.9.1167-a","article-title":"Bupropion and chronic aphthous ulceration","volume":"141","author":"Kast","year":"2005","journal-title":"Arch Dermatol"},{"issue":"2","key":"2020060307273242200_i2168-9709-8-4-188-b11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.5114\/pdia.2013.34158","article-title":"Recurrent aphthous stomatitis: genetic aspects of etiology","volume":"30","author":"Slebioda","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"issue":"9","key":"2020060307273242200_i2168-9709-8-4-188-b12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/j.1552-4604.1995.tb04132.x","article-title":"Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression","volume":"35","author":"Sweet","year":"1995","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2020060307273242200_i2168-9709-8-4-188-b13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.29046\/JJP.015.1.004","article-title":"The efficacy and toxicity of bupropion in the elderly","volume":"15","author":"Howard","year":"2000","journal-title":"Jefferson J Psychiatry"},{"issue":"6","key":"2020060307273242200_i2168-9709-8-4-188-b14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/00220345840630091001","article-title":"Whole-saliva secretion rates in old and young healthy subjects","volume":"63","author":"Ben-Aryeh","year":"1984","journal-title":"J Dent Res"},{"key":"2020060307273242200_i2168-9709-8-4-188-b15","doi-asserted-by":"crossref","unstructured":"Guggenheimer \n              J.\n            \n            \n              Moore P.\n              Xerostomia. \n            \n          \n          J Am Dent Assoc. 2003;134(1):61-9. DOI: 10.14219\/jada.archive.2003.0018.","DOI":"10.14219\/jada.archive.2003.0018"},{"issue":"2","key":"2020060307273242200_i2168-9709-8-4-188-b16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"2020060307273242200_i2168-9709-8-4-188-b17","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"2020060307273242200_i2168-9709-8-4-188-b18","unstructured":"Zyban [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2017."},{"issue":"Suppl 2","key":"2020060307273242200_i2168-9709-8-4-188-b19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-200262002-00002","article-title":"Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation","volume":"62","author":"Johnston","year":"2002","journal-title":"Drugs"},{"issue":"2","key":"2020060307273242200_i2168-9709-8-4-188-b20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/070674370204700208","article-title":"Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine","volume":"47","author":"Vanderkooy","year":"2002","journal-title":"Can J Psychiatry"},{"issue":"Spec No","key":"2020060307273242200_i2168-9709-8-4-188-b21","doi-asserted-by":"publisher","first-page":"680-8","DOI":"10.1177\/00220345870660S213","article-title":"Iatrogenic causes of salivary gland dysfunction","volume":"66","author":"Schubert","year":"1987","journal-title":"J Dent Res"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/4\/188\/2095067\/mhc_2018_07_188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/4\/188\/2095067\/mhc_2018_07_188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:20:19Z","timestamp":1731687619000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/8\/4\/article-p188.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2018.07.188","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}